Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 13/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | CA1 | P00915 | 1/20 | 0.51 |
| ▸ | CA2 | P00918 | 1/20 | 0.51 |
| ▸ | ACHE | P22303 | 1/20 | 0.51 |
| ▸ | CASP3 | P42574 | 1/20 | 0.46 |
| ▸ | MGLL | Q99685 | 1/20 | 0.43 |
| ▸ | PLAU | P00749 | 1/20 | 0.43 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1961986 | 0.87 | NPC1 (0.50) | NPC1RAB9ACA1CA2ACHE | |
| SCHEMBL14278347 | 0.86 | CA1 (0.49) | TRPV1NPC1RAB9ACA1CA2 | |
| SCHEMBL24192057 | 0.84 | TRPV1 (0.50) | TRPV1ALDH1A1 | |
| SCHEMBL2734026 | 0.82 | TRPV1 (0.55) | TRPV1 | |
| SCHEMBL4351760 | 0.82 | TRPV1 (0.55) | TRPV1 | |
| SCHEMBL1961942 | 0.82 | CA1 (0.52) | NPC1RAB9ACA1CA2ACHE | |
| SCHEMBL1963207 | 0.81 | CA1 (0.59) | NPC1RAB9ACA1CA2ACHE | |
| SCHEMBL472492 | 0.81 | CA1 (0.43) | TRPV1NPC1RAB9ACA1CA2 | |
| SCHEMBL472494 | 0.81 | CA1 (0.43) | TRPV1NPC1RAB9ACA1CA2 | |
| SCHEMBL13613606 | 0.80 | TRPV1 (0.59) | TRPV1OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4019485-A1 | METHOD FOR PRODUCING HETEROCYCLIDENE ACETAMIDE DERIVATIVES | Mochida Pharmaceutical Co., Ltd. (JP) | 2022-06-29 | — | — | EP | disclosed |
| US-20220009898-A1 | METHOD FOR PRODUCING HETEROCYCLIDENE ACETAMIDE DERIVATIVE | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2022-01-13 | — | — | US | disclosed |
| WO-2021038889-A1 | METHOD FOR PRODUCING HETEROCYCLIDENE ACETAMIDE DERIVATIVE | 持田製薬株式会社 | 2021-03-04 | — | — | WO | disclosed |
| EP-2412372-A1 | 2-Aminooxazole derivatives for use as TRPV1 antagonists for treating i.a. pain, inflammation, neurodegenerative diseases or gastrointestinal diseases | Abbott Laboratories (US) | 2012-02-01 | — | — | EP | disclosed |
| EP-1885704-B1 | ANTAGONISTS OF THE VANILLOID RECEPTOR SUBTYPE 1 (VR1) AND USES THEREOF | ABBOTT LAB (US) | 2011-09-28 | — | — | EP | disclosed |
| US-7998993-B2 | TRPV1 antagonists | ABBOTT LABORATORIES (US) | 2011-08-16 | — | — | US | disclosed |
| EP-2220059-B1 | 2-AMINOOXAZOLE DERIVATIVES AS TRPVL ANTAGONISTS USEFUL FOR TREATING PAIN | ABBOTT LAB (US) | 2011-08-03 | — | — | EP | disclosed |
| US-20110144057-A1 | ANTAGONISTS OF THE VANILLOID RECEPTOR SUBTYPE 1 (VR1) AND USE THEREOF | ABBOTT LABORATORIES (US) | 2011-06-16 | — | — | US | disclosed |
| US-7902236-B2 | Antagonists of the vanilloid receptor subtype 1 (VR1) and use thereof | ABBOTT LABORATORIES (US) | 2011-03-08 | — | — | US | disclosed |
| EP-2220059-A1 | 2-AMINOOXAZOLE DERIVATIVES AS TRPVL ANTAGONISTS USEFUL FOR TREATING PAIN | Abbott Laboratories (US) | 2010-08-25 | — | — | EP | disclosed |
| US-20100010055-A1 | ANTAGONISTS OF THE VANILLOID RECEPTOR SUBTYPE 1 (VR1) AND USE THEREOF | ABBOTT LABORATORIES (US) | 2010-01-14 | — | — | US | disclosed |
| US-20090124666-A1 | TRPV1 ANTAGONISTS | ABBOTT LABORATORIES (US) | 2009-05-14 | — | — | US | disclosed |
| WO-2009055749-A1 | 2-AMINOOXAZOLE DERIVATIVES AS TRPVL ANTAGONISTS USEFUL FOR TREATING PAIN | ABBOTT LABORATORIES (US) | 2009-04-30 | — | — | WO | disclosed |
| US-7504520-B2 | Antagonists of the vanilloid receptor subtype 1 (VR1) and use thereof | ABBOTT LABORATORIES (US) | 2009-03-17 | — | — | US | disclosed |
| EP-1885704-A2 | ANTAGONISTS OF THE VANILLOID RECEPTOR SUBTYPE 1 (VR1) AND USES THEREOF | Abbott Laboratories (US) | 2008-02-13 | — | — | EP | disclosed |
| US-20060281799-A1 | Antagonists of the vanilloid receptor subtype 1 (VR1) and use thereof | ABBVIE INC. | 2006-12-14 | — | — | US | disclosed |
| WO-2006122250-A2 | ANTAGONISTS OF THE VANILLOID RECEPTOR SUBTYPE 1 (VR1) AND USES THEREOF | ABBOTT LABORATORIES (US) | 2006-11-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060281799-A1 | Antagonists of the vanilloid receptor subtype 1 (VR1) and use thereof | TRPV1, TMEM109, CACNA1E | TRPV1 1/4885NPC1 1188/4885RAB9A 1195/4885 |
| US-20110144057-A1 | ANTAGONISTS OF THE VANILLOID RECEPTOR SUBTYPE 1 (VR1) AND USE THEREOF | TRPV1, TMEM109, CACNA1E | TRPV1 1/4885NPC1 1188/4885RAB9A 1195/4885 |
| US-20090124666-A1 | TRPV1 ANTAGONISTS | TRPV1, TRPV2, TRPV3 | TRPV1 1/4885NPC1 237/4885RAB9A 1734/4885 |
| US-20220009898-A1 | METHOD FOR PRODUCING HETEROCYCLIDENE ACETAMIDE DERIVATIVE | COASY, NAAA, AADAC | TRPV1 2623/4885NPC1 2609/4885RAB9A 1394/4885 |
| US-20100010055-A1 | ANTAGONISTS OF THE VANILLOID RECEPTOR SUBTYPE 1 (VR1) AND USE THEREOF | TRPV1, TMEM109, CACNA1E | TRPV1 1/4885NPC1 1188/4885RAB9A 1195/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.